| Pharmaceutical Information |
| Drug Name |
Mepolizumab |
| Drug ID |
BADD_D01389 |
| Description |
Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm3 or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue. Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases.[A221048, A221053, A221058, A221063, A221068, L16518]
Mepolizumab is a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518] |
| Indications and Usage |
Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patients aged 12 and older in whom eosinophilia is present for at least six months without an identifiable non-hematologic secondary cause.[L16518] |
| Marketing Status |
approved; investigational |
| ATC Code |
R03DX09 |
| DrugBank ID |
DB06612
|
| KEGG ID |
D04923
|
| MeSH ID |
C434107
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D03MTN
|
| NDC Product Code |
58437-004; 58437-009; 0173-0881; 49401-012; 0173-0892; 0173-0904 |
| UNII |
90Z2UF0E52
|
| Synonyms |
mepolizumab | Bosatria | SB-240563 | SB240563 | Nucala |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
196078-29-2 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
